Pozen Receives FDA Approval for Trial of Arthritis Drug
Posted April 21, 2006
CHAPEL HILL, N.C. — Pozen
has received approval from the Food and Drug Administration to launch a Phase III trial of a proposed arthritis drug.
PN 200 is designed to help arthritis patients who are at risk of developing gastric ulcers.
Pozen said it would launch the trial later this year.
PN 200 combines an acid inhibitor, proton pump inhibitor and a non-steroidal anti-inflammatory drug in one tablet.